Inbiose is Fast Tracking 7 HMOs from its Portfolio for use in Infant Formula and Health Markets
Inbiose announces that it has extended its offering to 7 human milk oligosaccharides for which efficient processes become available for large-scale manufacturing and commercialization. Long awaited by the baby food industry, the commercial availability of these HMOs will bring great new opportunities to further improve Infant Milk Formula and to get closer to the all-time gold standard, human breast milk.
GHENT, Belgium, Oct. 18, 2018 /PRNewswire-PRWeb/ -- Inbiose announces that it has extended its offering to 7 HMOs for which efficient processes become available for large-scale manufacturing and commercialization. This crowning achievement marks the completion of a 5-year strategic investment in developing our state of the art GlycoActives® platform.
Inbiose remains committed to unlocking the full potential of human milk oligosaccharides and other specialty carbohydrates. The GlycoActives® technology platform is proving its promise to quickly develop cost-effective industrial fermentation process to produce premium quality health ingredients.
In addition to fucosylated molecules 2'-fucosyllactose, 3-fucosyllactose and difucosyllactose, Inbiose technology is enabling large-scale production of Lacto-N-neo-tetraose (LNnT) and Lacto-N-tetraose (LNT) as well as the acidic HMOs 6'-sialyllactose (6'SL) and 3'-sialyllactose (3'SL).
Long awaited by the baby food industry, the commercial availability of these HMOs will bring great new opportunities to further improve Infant Milk Formula and to get closer to the all-time gold standard, human breast milk.
In 2016 Inbiose entered into a collaboration with DuPont Nutrition & Health on fucosyllactose for human nutrition. In December 2017, our 2'fucosyllactose received EU Novel Food approval and FDA no objection to GRAS notice in April 2018. The product which is marketed by DuPont under the brand name Care4UTM made great strides forward and is gaining wide acceptance on the market place, both in infant formula as well as in health products.
HMOs hold great promise now that scientific research unravels at fast pace the myriad of body processes whereby these molecules play an important role in the overall wellbeing and growth of a baby into a healthy person.
"We are excited being able to bring many more of the distinct health benefits that these HMOs can offer to the market place" said Professor Wim Soetaert, CEO and chairman.
"Our GlycoActives® technology platform gives Inbiose an unprecedented 'innovation power' to create novel specialty carbohydrate production processes. This is now becoming visible in our extended offering of HMOs" said Joeri Beauprez, CSO.
Inbiose offers partnerships with industry segment leaders to fast-track development, registration and commercialization of HMO products into baby food, cosmetics, nutrition, pharma, dietary supplements and therapeutics.
About Inbiose:
Inbiose is a 50-person-strong biotech company based in Ghent-Belgium. Inbiose has made its mark as a leader in the development of human milk oligosaccharides, which are of paramount importance for the health of babies and infants. The company develops cost-effective processes to produce HMOs and other specialty carbohydrates using its proprietary GlycoActives® high-productivity biotechnological platform. Inbiose has over 60 patent applications and continues to invest in a unique library of strains, tuned towards the production of specialty carbohydrates. Inbiose seeks partnerships with industry segment leaders to jointly bring more health ingredients to the market.
More information can be found at http://www.inbiose.com.
GlycoActives® is a registered trademark of Inbiose NV.
SOURCE Inbiose
Share this article